Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 6 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 97%

Switzerland Nachrichten Nachrichten

Switzerland Neuesten Nachrichten,Switzerland Schlagzeilen

Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.

Danaher stock was rising Tuesday after the healthcare company reported third-quarter earnings and revenue that topped Wall Street estimates.

In the same period last year, the company reported earnings of $2.56 a share on revenue of $7.66 billion.

 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 3. in CH

Switzerland Neuesten Nachrichten, Switzerland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

FMC Stock Tumbles on Revenue Warning Ahead of EarningsThe crop protection company cited lower sales in Latin America as a reason for lowering estimates.
Herkunft: MarketWatch - 🏆 3. / 97 Weiterlesen »

Agilysys’ stock jumps on revenue, earnings beatJon Swartz is a senior reporter for MarketWatch in San Francisco, covering many of the biggest players in tech, including Netflix, Facebook and Google. Jon has covered technology for more than 20 years, and previously worked for Barron's and USA Today. Follow him on Twitter jswartz.
Herkunft: MarketWatch - 🏆 3. / 97 Weiterlesen »

3M Posts Big Earnings Beat Following Recent Legal SettlementsInvestors have reacted to 3M's flurry of announcements by essentially avoiding the stock.
Herkunft: MarketWatch - 🏆 3. / 97 Weiterlesen »

Novartis lifts 2023 earnings forecast for third timeSwitzerland's Novartis (NOVN.S) on Tuesday raised its full-year earnings forecast for the third time, citing cost cuts and higher-than-forecast prices for a multiple sclerosis (MS) drug.
Herkunft: Reuters - 🏆 2. / 97 Weiterlesen »